StockData
Sangamo Therapeutics, Inc logo

Sangamo Therapeutics, Inc (SGMOQ) stock

SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)

Close on Oct 19, 2026Market cap $39.43MP/E –Yield –

Sangamo Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Sangamo Therapeutics's profit margin for the twelve months ending Mar 31, 2026 was -356.9%. For fiscal 2025 it was -310.8%, against -169.4% the year before. The highest annual figure on record is -57.6% in fiscal 2014.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-310.8%−141.4
FY2024Dec 31, 2024-169.4%−23.1
FY2023Dec 31, 2023-146.3%+26.5
FY2022Dec 31, 2022-172.8%−11.7
FY2021Dec 31, 2021-161.1%−58.7
FY2020Dec 31, 2020-102.4%−9.4
FY2019Dec 31, 2019-92.9%−12.0
FY2018Dec 31, 2018-80.9%+68.3
FY2017Dec 31, 2017-149.2%+220.4
FY2016Dec 31, 2016-369.6%−266.6
FY2015Dec 31, 2015-102.9%−45.4
FY2014Dec 31, 2014-57.6%+52.7
FY2013Dec 31, 2013-110.3%−7.5
FY2012Dec 31, 2012-102.8%+243.6
FY2011Dec 31, 2011-346.4%−227.0
FY2010Dec 31, 2010-119.5%−35.7
FY2009Dec 31, 2009-83.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 2026-2149.4%−1674.1
Q4 FY2025Dec 31, 2025-263.0%+46.8
Q3 FY2025Sep 30, 2025-6012.0%−6033.6
Q2 FY2025Jun 30, 2025-109.2%+10039.1
Q1 FY2025Mar 31, 2025-475.3%+9730.3
Q4 FY2024Dec 31, 2024-309.8%+2642.9
Q3 FY2024Sep 30, 202421.6%+1130.0
Q2 FY2024Jun 30, 2024-10148.3%−8473.0
Q1 FY2024Mar 31, 2024-10205.6%−10219.0
Q4 FY2023Dec 31, 2023-2952.7%−2761.9
Q3 FY2023Sep 30, 2023-1108.4%−907.5
Q2 FY2023Jun 30, 2023-1675.3%−1528.3
Q1 FY2023Mar 31, 202313.4%+169.2
Q4 FY2022Dec 31, 2022-190.9%−56.9
Q3 FY2022Sep 30, 2022-200.9%−33.9
Q2 FY2022Jun 30, 2022-147.0%+22.3
Q1 FY2022Mar 31, 2022-155.8%+19.0
Q4 FY2021Dec 31, 2021-134.0%+23.4
Q3 FY2021Sep 30, 2021-167.0%−164.3
Q2 FY2021Jun 30, 2021-169.2%−2.5
Q1 FY2021Mar 31, 2021-174.8%+153.4
Q4 FY2020Dec 31, 2020-157.4%−165.7
Q3 FY2020Sep 30, 2020-2.7%+121.7
Q2 FY2020Jun 30, 2020-166.7%+5.9
Q1 FY2020Mar 31, 2020-328.2%+194.1
Q4 FY2019Dec 31, 20198.3%+77.9
Q3 FY2019Sep 30, 2019-124.4%−69.9
Q2 FY2019Jun 30, 2019-172.6%−94.9
Q1 FY2019Mar 31, 2019-522.2%−362.5
Q4 FY2018Dec 31, 2018-69.5%+30.6
Q3 FY2018Sep 30, 2018-54.5%+50.1
Q2 FY2018Jun 30, 2018-77.7%+73.7
Q1 FY2018Mar 31, 2018-159.7%+325.9
Q4 FY2017Dec 31, 2017-100.1%+7.8
Q3 FY2017Sep 30, 2017-104.6%+567.2
Q2 FY2017Jun 30, 2017-151.4%+566.5
Q1 FY2017Mar 31, 2017-485.6%–
Q4 FY2016Dec 31, 2016-107.9%–
Q3 FY2016Sep 30, 2016-671.8%–
Q2 FY2016Jun 30, 2016-717.9%–

More Sangamo Therapeutics figures

See a number that looks wrong?